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Abstract 
Increased levels of serum pro-fibrotic cytokines have been reported in patients with systemic sclerosis (SSc). Some of 
these cytokines also play an important role in the differentiation and migration of eosinophils. The aim of this study 
was to determine whether eosinophilic inflammation is caused in SSc. We retrospectively reviewed the peripheral 
blood eosinophil counts in 70 untreated patients with SSc and compared them with those in patients with other 
major collagen diseases. We additionally evaluated a possible association with disease severity. Eosinophil counts 
were significantly higher levels in patients with SSc than in those with other collagen diseases, whereas total leuko-
cyte counts were not. Eosinophil counts correlated positively with both severe interstitial lung disease (ILD; r = 0.255, 
p = 0.033) and modified Rodnan total skin thickness score (m-Rodnan TSS) in SSc (r = 0.347, p = 0.003), but did not 
correlate with ILD severity in other collagen diseases. In conclusion, peripheral eosinophil counts were higher in 
patients with SSc than in those with other collagen diseases and were correlated with increased disease severity. Our 
data suggest that eosinophilic inflammation is involved in the pathogenesis and progression of SSc.
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Background
Systemic sclerosis (scleroderma, SSc) is an autoimmune 
connective tissue disorder characterized by microvascu-
lar injury, excessive fibrosis of the skin, and distinctive 
visceral changes involving the lungs, heart, kidneys, and 
gastrointestinal tract (Steen et al. 1994). Various clinical 
forms are recognized. These forms are generally clas-
sified into two major types on the basis of the extent of 
cutaneous fibrosis: (1) limited cutaneous SSc and (2) dif-
fuse cutaneous SSc (LeRoy et  al. 1988). Interstitial lung 
disease (ILD) and pulmonary hypertension (PH) are the 
most serious complications and common causes of pre-
mature death (Altman et al. 1991; Chang et al. 2003).
At present, several substances have been evaluated as 
biomarkers to assess the disease activity and its compli-
cations. Hasegawa et  al. previously reported that serum 
levels of interleukin (IL)-4, IL-10, and IL-13 were elevated 
in patients with SSc (Hasegawa et  al. 1997; Hasegawa 
1998). In addition, the current study has reported that 
serum levels of IL-13 were increased in patients with 
SSc and the increase was positively correlated with 
the severity of the disease activity (Vettori et  al. 2014). 
Other reports have suggested that serum levels of IL-33 
were significantly higher in early SSc patients and those 
cytokines may play a critical role of promoting fibrosis in 
patients with SSc (O’Reilly 2013; Vettori et al. 2014).
Meanwhile, some of these cytokines play a key role in 
the differentiation and migration of eosinophils (Dubois 
and Brujinzeel 1994; Pope et al. 2001; Chen et al. 2004). 
In addition, levels of circulating eosinophil cationic pro-
tein (ECP) were increased in patients with SSc compared 
with those in healthy controls, and eosinophil activation 
is part of the inflammatory process in SSc (Gustafsson 
et  al. 1991). In other words, such reports suggest that 
eosinophilic inflammation in patients might be caused 
in patients with SSc. However, controversy remains 
as to whether such inflammation might similarly be a 
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symptom of in other collagen diseases and what the rela-
tionship is between that inflammation and the mani-
festations of disease in SSc. Accordingly, to determine 
whether the eosinophilic inflammation is related to the 
pathogenesis of SSc, we retrospectively assessed eosino-
phil counts in the peripheral blood of untreated SSc 
patients and compared these counts with those of indi-
viduals with other collagen diseases.
Methods
Study sample
For this retrospective review, we investigated the records 
of all patients that were diagnosed with SSc up to March 
2013 in the Department of Rheumatology at Kameda 
Medical Center, a 1000 bed tertiary-care center. After 
screening, we identified 70 untreated SSc patients whose 
data were available for differential leukocyte counts, chest 
X-rays and computed tomography (CT). We excluded 
patients who lacked blood or imaging data, whose SSc 
treatment such as immunosuppressive agents had already 
been initiated, and who had comorbidities that potentially 
affected blood leukocyte and eosinophil counts such as 
infection, allergic or atopic diseases. SSc was diagnosed 
on the basis of American College of Rheumatology/Euro-
pean League Against Rheumatism (ACR/EULAR) 2013 
criteria (Van den Hoogen et  al. 2013) and the modified 
Rodnan total skin thickness score (m-Rodnan TSS) was 
assessed by two rheumatologists with twenty (TN) and 
forty (SM) years of experience in this field.
We compared eosinophil counts in 70 patients with 
SSc and in subjects with other major collagen diseases. 
Among these untreated patients, we identified 126 with 
rheumatoid arthritis (RA), 10 with polymyositis/dermat-
omyositis (PM/DM), 19 with primary Sjögren syndrome, 
20 with systemic lupus erythematosus (SLE), and eight 
with mixed connective tissue disease (MCTD) according 
to a protocol similar to that used for SSc.
The presence of ILD was confirmed by two pulmonolo-
gists and one radiologist. The severity of ILD was visually 
assessed by chest CT images by the two pulmonologists 
independently and classified for its vertical extent by 
referring to a previously established method (Nakashita 
et  al. 2014): grade 0, ILD not determined; grade 1, ILD 
extended across less than one-third of the lungs; grade 
2, ILD extended across more than one-third but less 
than two-thirds of the lungs, and grade 3, ILD extended 
across more than two-thirds of the lungs. When there 
were disagreements regarding findings between two pul-
monologists, an independent radiologist made the final 
determination of its severity. All clinical information was 
derived from medical records. This retrospective and 
observational study was approved by the ethics commit-
tee of our institution.
Statistical analyses
We used the Chi squared test or Mann–Whitney test to 
compare the two groups of patients. Correlations of leu-
kocyte and eosinophil counts with disease severity were 
evaluated by Spearman’s rank correlation analysis. To 
determine the factors correlated with eosinophil counts 
in patients with SSc, we used logistic regression multivar-
iable analysis. These analyses were performed using SPSS 
Version 21. Data were expressed as means with standard 
deviations (SD). For all statistical analyses, a p value less 
than 0.05 was considered significant.
Results
Characteristics of patients
The clinical characteristics of the 70 patients with SSc 
are summarized in Table 1. The mean ages (±SD) at the 
onset of SSc-related symptoms, at diagnosis and at evalu-
ation of eosinophil counts were 54.4 years (±12.1 years), 
54.4  years (±11.8  years) and 59.3  years (±11.8  years), 
respectively. Of the patients, 87  % were women and 
20 % had diffuse scleroderma. The mean modified Rod-
nan total skin thickness score (m-Rodnan TSS) was 6.2 
(±4.8), and ILD was confirmed in 24 patients (34  %). 
Half of the patients with ILD had grade 2 (nine patients) 
or more severe ILD (grade 3, three patients), whereas 
ILD could not be detected by chest X-ray in seven 
patients with grade 1 ILD. Mean blood leukocyte and 
eosinophil counts were 5857 (±1430) and 230 (±145)/
μL, respectively. Antinuclear, anti-topoisomerase I, and 
anti-centromere antibodies were positive in 92 % (49 of 
55 patients), 13 % (7 of 54 patients), and 61 % (34 of 56 
patients), respectively.
Leukocyte and eosinophil counts in patients with SSc 
and other collagen diseases
In our retrospective review, leukocyte counts were lower 
in patients with SSc (5857 ± 1430/μL) than in those with 
RA (6801 ± 1723/μL, p < 0.001), but this difference was 
not observed when compared with patients with PM/DM 
(5324 ± 1644/μL, p = 0.365), primary Sjögren syndrome 
(5660 ±  1563/μL, p =  0.538), or MCTD (5542 ±  1989/
μL, p = 0.491). In patients with SSc, there were no signif-
icant differences between limited and diffuse phenotypes 
(5807 ±  1391 vs. 6057 ±  1713/μL, p =  0.703) (Fig.  1a). 
However, eosinophil counts were higher in patients with 
SSc (230 ± 145/μL) than in those with RA (162 ± 125/
μL, p = 0.004), primary Sjögren syndrome (119 ± 73/μL, 
p = 0.005), or MCTD (76 ± 66/μL, p = 0.002). Patients 
with diffuse SSc had the highest levels of these counts 
among our subjects (312 ± 200/μL). In patients with SLE, 
both leukocyte (4622 ± 1981/μL) and eosinophil counts 
(57 ± 69/μL) were lower than in those with other colla-
gen diseases (Fig. 1b).
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The comparison between patients with and without 
ILD is shown in Fig. 1c. Eosinophil counts were no dif-
ferent between patients with and without ILD in RA 
(144 ± 91 vs. 127 ± 115/μL, p = 0.944) and those with 
other collagen diseases (96  ±  84 vs. 107  ±  102/μL, 
p =  0.715). In SSc, those levels were higher in patients 
with ILD than in those without ILD (275  ±  171 vs. 
201 ± 115/μL), but the difference was not statistically sig-
nificant (p = 0.092). We then performed the same analy-
sis between SSc patients with ILD grade ≥2 (n = 12) and 
<2 (n = 58). As a result, we noted that SSc patients with 
moderate (grade 2) or severe ILD (grade 3) had higher 
eosinophil counts than those with mild (grade 1) or no 
ILD (353 ± 204 vs. 205 ± 114/μL, p = 0. 018) (data not 
shown).
On the other hand, ILD was confirmed in 17 patients 
with SSc, 19 patients with RA and 17 patients with other 
collagen diseases by chest X-rays only, because mild ILD 
(grade 1) was difficult to be detected. We also performed 
the same analysis in the patients with and without ILD 
which was detected by chest X-rays, then eosinophil 
counts were higher in patients with ILD than in those 
without ILD (311 ± 196 vs. 205 ± 113/μL), but the statis-
tical analysis also showed no statistically significant dif-
ference (p = 0.053). As for the patients with RA and with 
other collagen diseases, those were not different between 
patients with and without ILD.
Correlation with the severity of disease
The correlation of ILD severity with eosinophil or leu-
kocyte counts in patients with SSc and RA is shown in 
Fig. 2. In SSc, ILD severity had a statistically significant 
positive correlation with eosinophil counts (r  =  0.255, 
p  =  0.033), but not with leukocyte counts (r  =  0.075, 
p  =  0.703). Meanwhile, in RA, neither eosinophil 
(r = 0.148, p = 0.502) nor leukocyte counts (r = −0.009, 
p = 0.966) were significantly correlated with ILD severity.
When we next examined m-Rodnan TSS relative to 
eosinophil counts and ILD grade in patients with SSc 
(Fig. 3). The m-Rodnan TSS showed similar positive cor-
relations to eosinophil counts and ILD grade (r = 0.347, 
p  =  0.003 and r  =  0.575, p  <  0.001). Clearly, patients 
with SSc had the highest eosinophil counts among all 
the subjects considered in the present study, and those 
Table 1 Baseline characteristics of patients with SSc
Plus minus data are presented as mean ± SD
GI gastrointestinal, CT computed tomography, ILD interstitial lung disease
a n/sample number
All patients (n = 70) Eosinophil >7 % (n = 7) Eosinophil <7 % (n = 63) p value
Age at evaluation of eosinophils (years) 59.3 ± 11.8 60.9 ± 11.9 59.3 ± 12.0 p = 0.681
Age at onset of SSc symptoms (years) 54.4 ± 12.1 53.8 ± 12.1 54.5 ± 12.1 p = 0.846
Age at diagnosis 54.5 ± 11.8 54.5 ± 7.5 54.6 ± 12.5 p = 0.864
Male/female sex (n) 9/61 0/7 9/54 p = 0.583
Diffuse scleroderma-related disease [n (%)] 14 (20) 3 (43) 11 (17) p = 0.137
Clinical findings
 m-Rodnan TSS 6.2 ± 4.8 11.1 ± 4.1 5.7 ± 7.0 p = 0.029
 Skin edema [n (%)] 47 (67) 5 (71) 42 (67) p = 1.0
 Skin pruritus [n (%)] 12 (17) 4 (57) 8 (13) p = 0.014
  Pulmonary hypertension [n (%)] 1 (1) 0 1 (2) p = 1.0
 GI involvement [n (%)] 9 (13) 1 (14) 8 (13) p = 1.0
Blood tests
 Total leukocyte counts (/μl) 5857 ± 1430 6100 ± 833 5830 ± 1516 p = 0.373
 Eosinophil counts (/μl) 230 ± 145 552 ± 97 195 ± 97 p < 0.001
 Positive for antinuclear antibody (>40) [na (%)] 49/55 (92) 5/5 (100) 44/50 (88) p = 1.0
 Positive for anti-topoisomerase I [na (%)] 7/54 (13) 1/5 (20) 6/49 (12) p = 0.515
 Positive for anti-centromere antibodies [na (%)] 34/56 (61) 3/5 (60) 31/51 (61) p = 1.0
CT findings
 Presence of ILD [n (%)] 24 (34) 5 (71) 23 (37) p = 0.107
 ILD grade ≥2 [n (%)] 12 (17) 4 (57) 8 (13) p = 0.014
X-ray findings
 Presence of ILD [n (%)] 17 (24) 5 (71) 12 (19) p = 0.008
 ILD grade ≥2 [n (%)] 12 (17) 4 (57) 8 (13) p = 0.014
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high counts correlated with the most severe categories of 
disease.
Comparison of SSc patients with above and within normal 
limits of eosinophil counts
To identify the clinical characteristics of SSc patients 
with high eosinophil counts, we grouped these subjects 
according to the percentage of eosinophils in leukocytes. 
Although the number of peripheral blood eosinophils in 
healthy people has been reported to be 15–650/μL, the 
normal range of percentage of peripheral blood eosino-
phil has not yet been described (Krause and Boggs 1987). 
We then classified SSc patients into those with counts 
above 7 % (n = 7) and within normal limits (n = 63) as 
a cut-off point, referring to the report by Schulte et  al. 
(2002), and compared their backgrounds (Table 1).
SSc patients with high eosinophil levels had higher 
m-Rodnan TSS values (11.1 vs. 5.7, p = 0.029) and pro-
portions of patients with skin pruritus (57 vs. 13  %, 
p =  0.014), and this group included a larger proportion 
of patients with moderate or severe ILD (57 vs. 13  %, 
p  =  0.014) than those within normal limits. A larger 
proportion of patients with the diffuse phenotype mani-
fested high eosinophil counts than those within the nor-
mal range, but not to a statistically significant extent (43 
vs. 17  %, p =  0.137). Age at onset of SSc symptoms, at 
diagnosis or at evaluation of eosinophil counts was not 
different between the two groups.
In the multivariate analysis, m-Rodnan TSS was deter-
mined as the factor that was independently associated 
with high eosinophil counts (hazard ratio [HR] 1.83; 95 % 
confidence interval [CI] 1.047–3.194, p  =  0.034); how-
ever, the relationship between ILD grade and eosinophil 
counts (HR 0.074; 95 % CI 0–1925.12, p = 0.615) did not 
prove to be statistically significant.
Discussion
The main findings of the present retrospective study were 
the following: (1) patients with SSc contained higher 
eosinophil counts than those with other major collagen 
Fig. 1 Peripheral blood leukocyte and eosinophil counts in SSc and other collagen diseases. Eosinophil counts were significantly higher in patients 
with SSc than those with RA, primary Sjögren syndrome (SjS), SLE or MCTD (b), but leukocyte counts did not follow that trend (a). Eosinophil counts 
were higher in patients with ILD than without ILD (275 vs. 201/μl, p = 0.092), but not in patients with RA or other collagen diseases (c) (†p < 0.05; 
††p < 0.01)
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diseases, and (2) eosinophil counts correlated positively 
with the severity of SSc. Accordingly, our data suggest 
that eosinophilic inflammation is involved in the patho-
genesis and progression of SSc, and certain cytokines 
that cause eosinophilic inflammation are possible targets 
for treating SSc.
In SSc, cytokines such as IL-4, IL-6, IL-10, IL-13 
and transforming growth factor-ß (TGF-ß) have been 
reported to play important pathogenic roles (Ludwicka 
et al. 1992; Needlemann et al. 1992; Patrick et al. 1995), 
and the serum levels of these cytokines have been shown 
to be higher in patients with SSc than in healthy vol-
unteers (Needlemann et  al. 1992; Hasegawa et  al. 1997; 
Hasegawa 1998). On the other hand, Chiardola et  al. 
investigated the prevalence of eosinophilia in RA, and 
reported that eosinophilia was not an indicator of the 
Fig. 2 Correlations of eosinophil and leukocyte counts with ILD severity in patients with SSc (a, c) and RA (b, d). Eosinophil counts positively cor-
related with ILD severity in SSc (a), but not in RA (b). Leukocyte counts did not correlate to a statistically significant extent in both SSc (c) and RA (d)
Fig. 3 Correlation of m-Rodnan TSS with eosinophil counts (a) and ILD severity (b). m-Rodnan TSS correlated positively with eosinophil counts 
(r = 0.347, p = 0.003) and ILD grade (r = 0.575, p < 0.001)
Page 6 of 8Ando et al. SpringerPlus  (2016) 5:1401 
severity of RA (Chiardola et al. 2008). Some cases of pri-
mary sjögren syndrome have been reported to be compli-
cated by eosinophilic inflammation; however, eosinophils 
have also been reported in biopsies of dermatomyositis 
lesions in 10–20 % of cases (Crowson et al. 2008; Waseda 
et al. 2015). However, the prevalence of eosinophils and 
the relationship with disease activity remain unclear. Our 
study similarly could not detect increased levels of eosin-
ophils in those diseases.
Meanwhile, in patients with SSc-ILD in particular, 
macrophage-induced cytokines such as IL-6 and tumor 
necrosis factor-alpha were elevated (Hasegawa et  al. 
1997; Hasegawa 1998). Subsequently, Hasegawa et  al. 
suggested that cytokines derived from type 2 T helper 
cells (Th2) and macrophages contributed to the patho-
genesis of SSc and that macrophage-induced cytokines 
induced the development of ILD (Hasegawa et  al. 1997; 
Hasegawa 1998). In addition, in previous clinical stud-
ies of SSc-ILD, the increased percentage of eosinophils 
in bronchoalveolar lavage fluid (BALF) was associated 
with decreased lung diffusing capacity for carbon mon-
oxide and increased mortality (Bouros et  al. 2002; Sil-
ver and Clements 2003). Hence, the inclusion criteria of 
patients in an important clinical trial yielded evidence of 
increased percentages of eosinophils in BALF (Tashkin 
et al. 2006), and an outgrowth of fibroblasts was observed 
in patients with an increased percentage of eosinophils 
in BALF (Scheja et al. 2007). In addition, in patients with 
bronchial asthma, we previously reported that the con-
centration of ECP and eosinophil-protein X (EPX) in 
sputum were higher than and significantly correlated 
with those in serum (Motojima et al. 1995; Koseki et al. 
1996). These reports suggest that peripheral blood eosin-
ophils counts can be affected by eosinophil accumulation 
in the lung, and thus denote that eosinophilic inflamma-
tion might be associated with the pathogenesis of SSc-
ILD. However, we could not verify the participation of 
eosinophils in the progression of ILD. On this point, we 
considered that our assessment of ILD was qualitative, 
not quantitative, and consequently, a measurement bias 
might have led to our conclusion. Therefore, we will eval-
uate these points further through in  vitro and prospec-
tive studies.
On the other hand, our data clearly determined that 
m-Rodnan TSS correlated with eosinophil counts as the 
independent factor, and was associated with elevated 
eosinophil counts. Gustafsson et al. examined skin biop-
sies by immunocytochemical techniques and reported 
that eosinophils were occasionally observed in samples 
of normal skin (from healthy control subjects). In addi-
tion, in patients with SSc, samples from unaffected areas 
revealed infiltration by eosinophils and extracellular 
deposits of ECP in the dermal layer, whereas the number 
of eosinophils was not increased in samples from areas of 
fibrotic skin (Gustafsson et al. 1991). In addition, eosino-
phils were reported to induce fibroblast proliferation, 
in contrast to neutrophils (Pincus et  al. 1987; Gustafs-
son et al. 1991), and current investigations revealed that 
eosinophils promoted the expression of TGF-β, which 
plays a key role in fibrosis as well as inducing an epithelial 
to mesenchymal transition (Gharaee-Kermani and Phan 
1998; Yasukawa et  al. 2013). In SSc, fibroblasts derived 
from BALF had a great capacity to migrate and produce 
extracellular matrix proteoglycans, which was associated 
with eosinophil (Ludwicka et  al. 1992). In other words, 
these previous reports suggest the possibility that eosino-
phil activation plays a role in the inflammatory process of 
SSc, and such inflammation induced the fibrosis. Accord-
ingly, although detailed mechanisms of SSc and the 
impact of eosinophil on its pathogenesis remain unclear, 
we consider that this inflammatory process could be a 
target for delineating these mechanisms of SSc.
Our study had some limitations. First, as it was a retro-
spective analysis, we could not verify and evaluate some 
important data, such as pulmonary function, BALF, and 
pathological features of ILD. In addition, despite recent 
reports that KL-6 can be used as a lung fibrosis sever-
ity marker, and that the presence of elevated CXCL11 in 
BALF could serve as a prognostic factor for the decline 
of pulmonary function in SS-ILD (Sfriso et  al. 2012; 
Kumánovics et al. 2014), we did not confirm those data 
nor determine serum pro-fibrotic cytokines such as IL-4 
and IL-13. Consequently, in the current study, we iden-
tified a relationship of SSc pathogenesis with eosinophil 
counts only, but further evaluation of other biomarkers 
should be conducted. Second, because we included only 
untreated patients, the number evaluated here was rela-
tively small, and we could not perform follow-up analy-
ses. Therefore, we could not analyze in detail the effect 
of treatment on eosinophil counts. In other words, to 
elucidate detailed mechanisms of SSc and the role of 
eosinophils in the pathogenesis of ILD, our retrospective 
data should be re-evaluated prospectively. In addition, 
because the majority of SSc-ILD is characterized by a 
pattern of nonspecific interstitial pneumonia (King 2005), 
there is a discrepancy between the characterization of 
BALF and pathological appraisals. Therefore, to evaluate 
these mechanisms, we are currently planning in vitro and 
in vivo studies as well as prospective investigation.
Conclusion
Our retrospective analysis revealed that levels of periph-
eral eosinophil counts were elevated in patients with SSc 
and were correlated with its severity. Considering previ-
ous reports, pro-fibrotic cytokines that cause eosino-
philic inflammation might play an important role within 
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the pathogenesis of SSc, and could be indicative of a 
treatment target.
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